Merck to Participate in the 11th Annual SVB Leerink Global Healthcare Conference Life Science Investing
Pivotal Phase 3 Data for KEYTRUDA® in High-Risk Early-Stage Triple-Negative Breast Cancer Published in the New England Journal of Medicine Pharmaceutical Investing
Johnson & Johnson to Participate in the Raymond James 43rd Annual Institutional Investors Conference Pharmaceutical Investing
Aurinia Pharmaceuticals to Release Fourth Quarter and Year End 2021 Financial Results on February 28, 2021 Pharmaceutical Investing
Bristol Myers Squibb Enters Into $5 Billion Aggregate Accelerated Share Repurchase Agreements Pharmaceutical Investing
Solta Medical Corporation Files Registration Statement for Proposed Initial Public Offering Pharmaceutical Investing
Jamieson Wellness Inc. Announces Date of Fourth Quarter and Full Year 2021 Financial Results and Conference Call Life Science Investing
Gilead to Present Latest Antiviral Research and Development Data at CROI 2022 Addressing Urgent Global Needs Pharmaceutical Investing
TRULANCE® for Irritable Bowel Syndrome with Constipation in Adults is now Available to Canadians to Help Meet Treatment Gap that leaves 70 Per cent of Patients Unsatisfied Pharmaceutical Investing
Bristol Myers Squibb Awards Nearly $8 Million in New Health Equity Grants to Improve Access to Care for Medically Underserved Patients in U.S. Pharmaceutical Investing
Merck and Ridgeback Announce That 3.1 Million Courses of Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Have Been Supplied to the U.S. Government for Use in the United States Pharmaceutical Investing
